ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1859

Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody

Jun Nakamura, Takao Nagashima and Kojiro Sato, Jichi Medical University, Shimotsuke, Japan

Meeting: ACR Convergence 2022

Keywords: Biomarkers, dermatomyositis, interstitial lung disease, prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Muscle Biology, Myositis and Myopathies Poster II

Session Type: Poster Session D

Session Time: 1:00PM-3:00PM

Background/Purpose: Interstitial Lung Disease (ILD) accompanied with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM) is usually rapidly progressive and life-threatening with poor prognosis. Although serum ferritin has been reported as a prognostic marker for ILD among patients with anti-MDA5 antibody positive DM, serum ferritin levels does not necessarily correlate with disease activity of ILD in some patients. Beta-2 microglobulin (β2MG) is a light chain molecule of the MHC-class I, and urinary β2MG is often used as a marker for tubular damage in kidney. It is also known to be elevated in malignant tumors, infectious diseases, and autoimmune diseases such as juvenile idiopathic arthritis. In this study, we assessed the utility of urinary β2MG as a disease activity marker or a prognostic marker in anti-MDA5 antibody-positive DM with ILD.

Methods: This retrospective study included patients with anti-MDA5 antibody-positive DM who admitted to our division from January 2004 to March 2022. Data of Urinary β2MG and serum ferritin were measured before treatment, and these were serially examined during induction treatment. The values were used that obtained within 200 days after the hospitalization.

Results: The median age of the patient was 51 (range, 20-85years), and numbers of women was 35 (66%).Of the 55 patients with anti-MDA5 positive patients, 53 patients were tested for urinary β2MG at the time of diagnosis. Thirty-three patients (70%) survived and 16 (30%) died during induction treatment. The treatment included glucocorticoid, cyclosporin, tacrolimus, intravenous cyclophosphamide, methotrexate, azathioprine, infliximab, baricitinib and plasmapheresis. The median age of the patients did not differ between patients who survived and those who died (50 and 53.5 yrs old, respectively). Urinary β2MG levels before treatment were significantly lower in the survived patients than those in the dead patients (499 and 1698 mg/gCr, respectively, p=0.025, Fig. 1(a)). Serum creatine and KL-6 did not differ between the groups (0.62 and 0.55 mg/dl, 756 and 887.6 U/ml, respectively). Urinary β2MG significantly decreased in the survived patients, while it increased in the dead patients despite intensive treatments (Fig. 2(a)). In contrast, there was no difference in serum ferritin levels before treatment between patients who survived and those who died (806 and 1622 ng/ml, respectively, p=0.09, Fig 1(b)). Serum ferritin levels did not statistically decrease by treatment in both groups (Fig 2(b)).

Conclusion: Elevated urinary β2MG level is a poor prognostic marker in patients with anti-MDA5 antibody-positive DM who have ILD. Furthermore, increase of urinary β2MG after treatment indicates resistance to treatment and fatal outcome.

Supporting image 1

Figure 1. Urinary β2MG and serum ferritin in the survival and death groups

Supporting image 2

Figure 2. Changes in urinary β2MG and serum ferritin levels before and after treatment in the two groups


Disclosures: J. Nakamura, None; T. Nagashima, None; K. Sato, None.

To cite this abstract in AMA style:

Nakamura J, Nagashima T, Sato K. Urinary Beta-2 Microglobulin Is a Sensitive Prognostic Marker in Dermatomyositis Patients with Interstitial Lung Disease Positive for Anti-MDA-5 Antibody [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/urinary-beta-2-microglobulin-is-a-sensitive-prognostic-marker-in-dermatomyositis-patients-with-interstitial-lung-disease-positive-for-anti-mda-5-antibody/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/urinary-beta-2-microglobulin-is-a-sensitive-prognostic-marker-in-dermatomyositis-patients-with-interstitial-lung-disease-positive-for-anti-mda-5-antibody/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology